Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

NCT07476326 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Bmab1700
DRUG: Opdivo

Sponsor

Biocon Biologics UK PLC